Introduction
Tixagevimab/cilgavimab, infection
ASYMPTOMATIC COVID-19, DISEASE CAUSED BY SARS-COV-2, INFECTION
COVID-19 vaccines have dramatically reduced the severity of disease caused by SARS-CoV-2 infection [Tixagevimab/cilgavimab (AZD7442; Evusheld, subsequently referred to as T/C), a combination of two long-acting monoclonal antibodies, AZD8895 and AZD1061 (AstraZeneca), was shown in the PROVENT trial to reduce the risk of symptomatic COVID-19 infection by 83% compared with placebo among unvaccinated and relatively healthy patients [The authorization of T/C coincided with the emergence of the first Omicron variant, which resulted in previously effective monoclonal antibodies, including T/C, losing effectiveness [